Oxymorphone Hydrochloride Tablet
Product Images NDC 72865-130

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxymorphone Hydrochloride (NDC 72865-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

10 mg- 100 Count (Oxymorphone 10 mg)

10 mg- 100 Count (Oxymorphone 10 mg)
Each tablet contains 10 mg of Oxymorphone Hydrochloride USP. See package insert for complete prescribing information. Usual dosage information is not available. The tablets should be stored in a container with a child-resistant closure at a temperature between 20°C-25°C (68°F-77°F) as defined in the USP with a light-resistant covering. Do not accept if seal is broken or missing. Manufactured for XICare Pharmaceuticals Inc, located at 242 South Culver Street, Suite 202, Lawrenceville, GA 30046. The medication guide should be dispensed separately to each patient by the pharmacist. This medicine is manufactured by Ascent Pharmaceuticals Inc and is only available by prescription. NDC 72865-131-01. Rev: 10/19.*
FDA Label Image

5 mg- 100 Count (Oxymorphone 5 mg)

5 mg- 100 Count (Oxymorphone 5 mg)
XLcare Pharmaceuticals Inc has manufactured Oxymorphone Hydrochloride tablets which contain 5mg of Oxymerphone Hydrochloride each. The tablets come in a light-resistant container with a child-resistant closure. The medication guide must be provided to each patient by the pharmacist. The full prescribing information is in the package insert, and the tablets should be stored between 20°C-25°C (68°F-77°F). The manufacturer is XLCare PharmaceuticaIs, Inc, and the tablets were manufactured by Ascent Pharmaceuticals. Inc, Central Tship, NY 11722.*
FDA Label Image

Structure (Struct)

Structure (Struct)
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
Table 1 shows the adverse reactions reported in placebo-controlled trials for Oxymorphone Hydrochloride Tablets. The MedDRA Preferred Terms and the percentage of patients reporting adverse reactions are listed. Adverse reactions to Oxymorphone Hydrochloride Tablets reported in the trials include nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
This text describes the potential interactions and side effects of oxymorphone hydrochloride tablets with various substances including alcohol, benzodiazepines and other CNS depressants, serotonergic drugs, MAO inhibitors, mixed agonist/antagonist and partial agonist opioid analgesics, muscle relaxants, diuretics, and cimetidine. These interactions can lead to increased risk of hypotension, respiratory depression, sedation, coma, and death. Patients are advised to avoid alcohol and certain medications while taking oxymorphone hydrochloride tablets and closely monitor any signs of respiratory depression or sedation.*
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
Table 3 shows the pharmacokinetic parameters of Oxymorphone Hydrochloride tablets, including dosage, concentration, area under the curve, and half-life. The table compares the parameters for single doses of 5mg, 10mg, and 20mg, and multiple doses of 5mg, 10mg, and 20mg every 6 hours for 5 days. Not available results are indicated where applicable.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.